Lasmiditan and Different Triptans in Menstrual Migraine: A Bayesian Network Meta-analysis.

IF 4.1 2区医学 Q1 CLINICAL NEUROLOGY

Pain and Therapy Pub Date : 2025-04-01 Epub Date: 2025-02-24 DOI:10.1007/s40122-025-00705-x

Zhaoming Song, Yanao Guo, Jingyu Gu, Chen Yang, Ruisi Qu, Jian Li, Zhouqing Chen, Zhong Wang

{"title":"Lasmiditan and Different Triptans in Menstrual Migraine: A Bayesian Network Meta-analysis.","authors":"Zhaoming Song, Yanao Guo, Jingyu Gu, Chen Yang, Ruisi Qu, Jian Li, Zhouqing Chen, Zhong Wang","doi":"10.1007/s40122-025-00705-x","DOIUrl":null,"url":null,"abstract":"Introduction: Menstrual migraine (MM) is a common subtype of migraine that greatly affects a woman's quality of life. A number of different drugs are used to treat menstrual migraine, but it is not known which is more effective.Methods: In this study, we searched all randomized controlled trials that satisfied the inclusion and exclusion criteria up to December 2023 on PubMed, Embase and Cochrane Library using a suitable search strategy. We constructed a suitable network model for analysis after evaluating the heterogeneity among the included direct, indirect and pooled evidence. Odds ratio (OR) and corresponding 95% confidence intervals (CI) were used as valid indicators for this network meta-analysis.Results: In the Bayesian network model we constructed, we found that lasmiditan (vs. placebo OR, 14; 95% CI 3.1-100) was better than rizatriptan (vs. placebo OR, 1.9; 95% CI 1.2-3.3) in terms of the rate of sustained freedom from pain. There was no statistically significant difference between lasmiditan and different triptans in terms of the rate of being pain-free at 2 h (2-h pain-free) and the rate of pain relief at 2 h (2-h pain relief). Regarding safety, the probability of adverse events was significantly higher for rizatriptan (OR, 2.7; 95% CI 1.1-7.3) than for placebo.Conclusion: In terms of treatment efficacy for MM, lasmiditan was not worse than different triptans and was even better than some of the triptans in the rate of sustained freedom from pain. As an emerging treatment, lasmiditan is promising for the treatment of MM. However, more research needs to be carried out because of the lack of safety analysis for lasmiditan.","PeriodicalId":19908,"journal":{"name":"Pain and Therapy","volume":" ","pages":"639-653"},"PeriodicalIF":4.1000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11914705/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pain and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40122-025-00705-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Menstrual migraine (MM) is a common subtype of migraine that greatly affects a woman's quality of life. A number of different drugs are used to treat menstrual migraine, but it is not known which is more effective.

Methods: In this study, we searched all randomized controlled trials that satisfied the inclusion and exclusion criteria up to December 2023 on PubMed, Embase and Cochrane Library using a suitable search strategy. We constructed a suitable network model for analysis after evaluating the heterogeneity among the included direct, indirect and pooled evidence. Odds ratio (OR) and corresponding 95% confidence intervals (CI) were used as valid indicators for this network meta-analysis.

Results: In the Bayesian network model we constructed, we found that lasmiditan (vs. placebo OR, 14; 95% CI 3.1-100) was better than rizatriptan (vs. placebo OR, 1.9; 95% CI 1.2-3.3) in terms of the rate of sustained freedom from pain. There was no statistically significant difference between lasmiditan and different triptans in terms of the rate of being pain-free at 2 h (2-h pain-free) and the rate of pain relief at 2 h (2-h pain relief). Regarding safety, the probability of adverse events was significantly higher for rizatriptan (OR, 2.7; 95% CI 1.1-7.3) than for placebo.

Conclusion: In terms of treatment efficacy for MM, lasmiditan was not worse than different triptans and was even better than some of the triptans in the rate of sustained freedom from pain. As an emerging treatment, lasmiditan is promising for the treatment of MM. However, more research needs to be carried out because of the lack of safety analysis for lasmiditan.

查看原文本刊更多论文

拉斯米坦和不同曲坦类药物治疗经期偏头痛：贝叶斯网络荟萃分析。

月经期偏头痛（MM）是一种常见的偏头痛亚型，严重影响女性的生活质量。许多不同的药物用于治疗经期偏头痛，但尚不清楚哪种药物更有效。方法：在本研究中，我们使用合适的检索策略，检索PubMed、Embase和Cochrane Library中截至2023年12月满足纳入和排除标准的所有随机对照试验。在评估了直接证据、间接证据和汇集证据之间的异质性后，我们构建了一个合适的网络模型进行分析。比值比（OR）和相应的95%置信区间（CI）作为本网络meta分析的有效指标。结果：在我们构建的贝叶斯网络模型中，我们发现拉斯米坦(vs安慰剂OR, 14；95% CI 3.1-100)优于利扎曲坦(vs安慰剂OR， 1.9；95% CI 1.2-3.3)，持续摆脱疼痛的比率。拉斯米坦与不同曲坦类药物在2 h无痛率（2-h pain-free）和2 h疼痛缓解率（2-h pain relief）方面无统计学差异。在安全性方面，利扎曲坦的不良事件发生率明显更高(OR, 2.7；95% CI 1.1-7.3)。结论：在治疗MM的疗效方面，拉斯米坦并不差于其他曲坦类药物，甚至在持续镇痛率方面优于部分曲坦类药物。拉斯米坦作为一种新兴的治疗方法，在治疗MM方面有很好的前景，但由于缺乏拉斯米坦的安全性分析，需要进行更多的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pain and Therapy CLINICAL NEUROLOGY-

CiteScore

6.60

自引率

5.00%

发文量

110

审稿时长

6 weeks

期刊介绍： Pain and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of pain therapies and pain-related devices. Studies relating to diagnosis, pharmacoeconomics, public health, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to, acute pain, cancer pain, chronic pain, headache and migraine, neuropathic pain, opioids, palliative care and pain ethics, peri- and post-operative pain as well as rheumatic pain and fibromyalgia. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports, trial protocols, short communications such as commentaries and editorials, and letters. The journal is read by a global audience and receives submissions from around the world. Pain and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.